NCT07413939 2026-03-10
BREnnA
Hoffmann-La Roche
Phase 2/3 Not yet recruiting
Clinical Trials
17 trialsNCT07461454 2026-03-10
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Not yet recruiting
NCT07417241 2026-02-18
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07406542 2026-02-12
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT07340541 2026-02-09
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07366840 2026-01-26
BRIGHT
Fudan University
Phase 2/3 Not yet recruiting
NCT07019337 2025-06-13
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07021261 2025-06-13
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients
Fudan University
Phase 3 Not yet recruiting
NCT06787339 2025-01-22
Calorite
Fudan University
Phase 2 Not yet recruiting
NCT06561607 2024-08-20
A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT06483386 2024-07-03
Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06475443 2024-06-26
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06229067 2024-01-29
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05901935 2023-06-13
DP303c in Patients With HER2-positive Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT05131893 2021-11-23
Neoadjuvant Treatment of Breast Cancer
National Institute of Oncology, Hungary
Not yet recruiting
NCT04922008 2021-06-10
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
Fudan University
Phase 2 Not yet recruiting
NCT04337658 2020-04-08
FAVOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Not yet recruiting